New long-term Leqvio data from ORION-8 study, presented at ESC congress, demonstrates consistent efficacy and safety beyond six years – Novartis
Novartis announced new long-term data from ORION-8, a Phase III open-label extension of ORION-9, ORION-10, ORION-11 and ORION-3 trials. The data demonstrated that with twice-yearly dosing (after an… read more.
